FDA Approval: Taletrectinib and ROS1 NSCLC
from Lung Cancer Considered Hosted by IASLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of taletrectinib, a next-generation ROS1 kinase inhibitor, for NSCLC with a ROS1 gene fusion. Dr. Enriqueta Felip and Dr. Jorge Nieva join the conversation to help review the data and offer help place this new agent in the proper perspective.
Embed this episode
No transcript yet.
Similar podcasts
Frequently asked questions
How long is this episode of Lung Cancer Considered?
This episode is 29 minutes long.
When was this Lung Cancer Considered episode published?
This episode was published on June 24, 2025.
Can I download this Lung Cancer Considered episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.